BioCentury
ARTICLE | Company News

DNX Biopharmaceuticals, XL-protein deal

August 3, 2015 7:00 AM UTC

The companies partnered to develop and commercialize long-acting biopharmaceutical products. XL-protein will contribute PASylation, its half-life extension technology, and undisclosed molecules that h...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article